Evidence map›Paper›PMID 34915785›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2022

Design, synthesis, and biological evaluation of biotinylated colchicine derivatives as potential antitumor agents.

Chao Wang, Yujing Zhang, Zeyu Wang, Yuelin Li, Qi Guan, Dongming Xing, Weige Zhang

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Chao WangThe Affiliated Hospital of Qingdao University, Cancer Institute, Qingdao University, Qingdao, Shandong, China.
Yujing ZhangThe Affiliated Cardiovascular Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, China.
Zeyu WangKey Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
Yuelin LiKey Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
Qi GuanKey Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
Dongming XingThe Affiliated Hospital of Qingdao University, Cancer Institute, Qingdao University, Qingdao, Shandong, China.
Weige ZhangKey Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemical drug design based on the biochemical characteristics of cancer cells has become an important strategy for discovering new anti-tumour drugs to improve tumour targeting effects and reduce off-target toxicities. Colchicine is one of the most prominent and historically microtubule-targeting drugs, but its clinical applications are hindered by notorious adverse effects. In this study, we presented a novel tumour-specific conjugate

Indexed as

Drug DesignAnimalsAntineoplastic AgentsBiotinBiotinylationCell ProliferationCells, CulturedColchicineDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMiceMolecular StructurePolymerizationStructure-Activity RelationshipTubulinAntineoplastic AgentsBiotinColchicineTubulinTubulin Modulatorsadverse effectsbiotinColchicineconjugatedisulphide bond

Identifiers

PMID34915785
PMCPMC8725855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.